| |||||||||
|
80%
agree
|
Organon was expensive acquisition for Schering-Plough |
|
0%
agree
|
merck acquisition |
|
25%
agree
|
Pipeline does not have a strong outlook |
![]()
|
|||||||||||||||||
| ||||||